Document is current
Any future updates will be listed below
-
Authors
Bose, Suman https://orcid.org/0000-0002-5921-3436
Volpatti, Lisa R.
Thiono, Devina
Yesilyurt, Volkan
McGladrigan, Collin
Tang, Yaoyu
Facklam, Amanda https://orcid.org/0000-0002-4519-4158
Wang, Amy
Jhunjhunwala, Siddharth https://orcid.org/0000-0001-8046-2288
Veiseh, Omid https://orcid.org/0000-0003-1153-8079
Hollister-Lock, Jennifer
Bhattacharya, Chandrabali
Weir, Gordon C.
Greiner, Dale L.
Langer, Robert https://orcid.org/0000-0003-4255-0492
Anderson, Daniel G. https://orcid.org/0000-0001-5629-4798
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (K99EB025254)
JDRF (PDF-2015-90-A-N, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B, 2-SRA-2019-714-S-B)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK104218)
- License Information
-
More Information
Article History
Received: 19 June 2019
Accepted: 18 February 2020
First Online: 30 March 2020
Competing interests
: D.G.A., R.L. and O.V. are founding scientists of Sigilon Therapeutics—a biotechnology company based in Cambridge, Massachusetts, United States that produces anti-fibrotic materials for cell-based therapies. For a list of entities with which R.L. is involved, compensated or uncompensated, see .
